National immunization program: vaccination, compliance and pharmacovigilance by Domingues, Carla Magda Allan S. et al.
Rev. Inst. Med. Trop. Sao Paulo
54(Suppl. 18):S22-S27, October, 2012
Presented at the I International Symposium on Dengue of the School of Medicine University of São Paulo on October 6, 2011.
(1) Secretariat of Health Surveillance, Ministry of Health, Brasília, DF, Brazil; 
(2) Center for Tropical Medicine, University of Brasília, Brasília, Brazil.
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The vaccine is one of the main control measures available for a major 
portion of infectious and transmissible diseases. It stands out as one of 
the great discoveries of public health for the benefit of the population. 
In Brazil, more than two centuries have passed since the first time 
(1804) the vaccine was administered as a control measure to prevent 
smallpox. Exactly a century later (1904), an epidemic of this disease 
led the President of the Republic Rodrigues Alves, to establish the 
obligation of the vaccination. In the same year, the hygienist Osvaldo 
Cruz coordinated the mass vaccination of the Rio de Janeiro`s population 
in order to control the epidemic. This movement generated a historical 
episode known as “The Vaccine Revolt” characterized by population 
rebellion and rejection to the measure adopted, culminating in the 
suspension of mandatory vaccination1,2. 
In this same century (XX), especially in the first half, epidemics 
of several diseases had been occurring in the country. It was also the 
moment that began the production and/or introduction of new vaccines 
in the country, when the first positive results appeared in control of 
some epidemics, elimination and eradication of diseases. Among the 
accomplishments of that time includes the introduction of yellow fever 
vaccine in 1937 with the interruption of urban-form disease transmission 
five years later (1942); the introduction of diphtheria-tetanus toxoids-
cellular pertussis vaccine (DTP), tetanus toxoid (TT) in 1950 for the 
prevention of tetanus, diphtheria and pertussis, diseases considered 
under control. 
Early in the second half of that century poliomyelitis vaccine was 
introduced with the first mass vaccination campaign conducted in the 
cities of Petrópolis, state of Rio de Janeiro (RJ) and Santo André, state of 
São Paulo (SP) in 19611 and also monovalent measles vaccine deployed in 
1967 and 1968, and that disease is currently in the process of certifying 
their eradication in the country. 
Regarding to smallpox, the last case reported in Brazil occurred in 
1971 and the international certification of eradication was granted by 
the World Health Organization – WHO in 1973. The global eradication 
stood out as the first major victory for the public health. 
During this period, if on the one hand successes were already seen by 
the use of vaccines for control, elimination and eradication of diseases, 
on the other hand, the lack or insufficient products to combat other 
diseases was the subject of pressure in the sector. A remarkable fact was 
an epidemic of meningococcal meningitis that spread in the country in 
the mid 70’s, the so-called “epidemic under censorship”. The insufficient 
doses of vaccines in the country and of the capacity to import vaccine 
doses to attend the population, made the current military government to 
prevent any disclosure of the fact in the media. However, this was only 
possible while the occurrence of cases did not reach different social strata 
of the population; when this began to occur, the information reached 
the media, which generated population pressure on the government3,4. 
Despite these contrasts, it was in this context that important 
advances occurred regarding the organization of the structure and 
actions of immunization in Brazil. In the early 70’s (1973) the National 
Immunization Program (NIP) was created linked to the National Division 
of Epidemiology and Health Statistics of the Ministry of Health. This 
aimed to arrange in a single sector immunization activities formerly 
structured in isolated programs of disease control, especially the 
vaccination campaign against smallpox and the National Plan for the 
Control of Poliomyelitis (PNCP). It was regulated by Decree 78.231 of 
August 1976 and was the first official immunization schedule published 
in 1977 by Ministerial Decree nº 452/1977 setting out the mandatory 
vaccines for children under one year old: tuberculosis, poliomyelitis, 
measles, diphtheria, tetanus and pertussis.
The 80’s were characterized by the creation of the National Institute 
for Quality Control in Health (INCQS) in 1981, the National Center for 
Distribution and Storage (Cenade), in Bio-Manguinhos/Fiocruz in 1982 
and the National Self-Sufficiency Program in Immunobiologics in 1985. 
They were intended to garantee the quality of the vaccines offered to the 
population, to strengthen the capacity of production and self-sufficiency 
by the national laboratories1,5,6. 
Another achievement was regarding poliomyelitis. The last case was 
reported in Brazil in 1989. Factors such as the National Poliomyelitis 
Control Plan established in 1971, the introduction of the oral poliomyelitis 
vaccine (OPV) from 1974 and the adoption of mass vaccination national 
days in 1980, led to the second major victory in the field of immunization. 
The disease has been certified as eradicated as the circulation of wild 
viruses in the Americas in 19941,7. 
Until then, NIP aimed to target primarily the pediatric population. 
However, with the expansion of the capacity of vaccine’s manufacturers, 
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the epidemiological surveillance and improvement in vaccination coverages 
allowed the reduction of vaccine-preventable diseases’ incidence; new 
products have been gradually incorporated into the list of immunobiological 
products already available. New vaccines were included and new 
immunization schedules were published boosting the supply of existing 
vaccines for other target groups in the national schedule. 
Still at the end of the last century, in the early years of the 90’s, 
hepatitis B vaccination has been initiated in areas of high endemicity. 
Than in 1996, new strategies were defined in relation to hepatitis B 
vaccination. This should target children under one year of age throughout 
the country and extend to those under 15 years old in the Legal Amazon, 
Santa Catarina, Espírito Santo and Federal District. 
Since 1999, immunization with seasonal influenza vaccine was 
initiated for the elderly from 65 years of age and, in the following year, 
was extended to the elderly from 60 years of age. In that same year 
(1999), the combined diphtheria and tetanus toxoids vaccine (dT) began 
to compose the national immunization schedule for the population from 
the age of seven, replacing the tetanus toxoid. 
In 2004, Ordinance 457/2004 established rules to the immunization 
schedules in a life cycle: children; adolescents; adults and elderly subjects, 
thus demonstrating that the vaccine in the country was already in fact 
an input available to the whole family. This included definitely in the 
routine the MMR vaccine (measles, rubella and mumps vaccine) in order 
to replace the monovalent measles vaccine and was recommended for 
children completing one year of age, followed by a second dose between 
four and six years and also included adolescents and adults, subjects 
not vaccinated in the childhood. It is worth mentioning that the MMR 
vaccination started in the year 1992 to the year 2000 progressively by 
the Brazilians states, through campaigns for children between one and 
11 years of age. 
In 2006, by the Ordinance 1,602/2006 a new vaccine was included, 
the oral human rotavirus vaccine (RHV) in the schedule for children 
from six to 24 weeks of age. 
In 2008 a national campaign was performed to reach the goal to 
the elimination of Rubella and the congenital rubella syndrome (CRS), 
beyond aiming to consolidate the strategy to eliminate measles in the 
country, targeting the susceptible adult groups. 
In 2010, Ordinance 3,318/2010 was published incorporating to the 
routine pediatric schedule Pneumococcal conjugate 10-valent (PCV10) 
and Meningococcal C conjugate vaccines, as the goal of the Strategic 
Plan for Development of the Ministry of Health (PAC Mais Saúde). 
The Pandemic Influenza A (H1N1)2009 national immunization 
campaign performed in 2010, 89.5 million persons, considered the 
most vulnerable groups to get sick or die from the disease (pregnant 
women, children between six months and two years old, health workers, 
indigenous and persons with chronic diseases), were vaccinated and 
this represented 46.9% of the total population of the country. In 2011, 
the influenza vaccine has been extended to these same priority groups.
In this same year, vaccination to hepatitis B was also expanded for 
people between 20 and 24 years of age, whereas since the mid-2000’s 
this had been extended to children and adolescents up to the age of 19 
years across the country. 
It is noteworthy that, in general, the introduction of new vaccines 
in the country is based on epidemiological, economic, safety, efficacy 
and logistic criteria. Studies of cost-effectiveness are important to help 
prioritize the deployment of vaccines demonstrating the interest of NIP 
to make decision based on scientific evidence. Currently, NIP offers 44 
different types of immunobiological products, including vaccines and 
homologous and heterologous sera. 
In accordance with the principles of universality and fairness of the 
Unified Health System (SUS), the Ordinance 1,946/2010 regulates a 
different schedule for indigenous population that, given the increased 
vulnerability of this population to disease, get benefits from products 
not yet routinely available to the general population. Therefore, in 
1993 the implementation of the Special Immunobiologicals Reference 
Centers (CRIES) was initiated. It consists of 42 vaccine rooms that 
offer immunobiologicals for people with special medical conditions, 
not available in the routine immunization services; also, these are 
considered reference centers to manage serious adverse events following 
immunization (AEFI). 
Regarding the history of organizational structure, NIP was bound 
in different organs in the Ministry of Health, and remains as a strong 
structure in public health policy of the country with advances in all 
aspects to fulfill the important mission to vaccinate the population. 
In 2003, with the creation of the Secretariat of Health Surveillance, 
this is currently linked to the Department of Transmissible Disease 
Surveillance occupying the position of General Coordination (Decree 
7,530 of July 2011). Under the federal units and cities, it is organized 
in different structures, usually linked to the area of Health Surveillance. 
It has a service network consisting of approximately 34,000 vaccine 
rooms distributed in 5,565 cities. To reach the population, different 
immunization strategies are used: routine, campaigns, intensification and 
vaccinal blocking, the latter ones upon outbreak occurrence. 
The financing of the actions is among the priorities of Ministry of 
Health with resources defined in the annual budget, in a separate item 
for the purchase of immunobiologicals, and for such purpose, not subject 
to budget cutting, as per Budget Guidelines Law – LDO nº 12,465 of 
12/Aug/2011, section I, nº 618. Considering the period from 1995 to 
2010, the resources spent on the acquisition of immunobiologicals 
exceed the figure of one billion reais, given the gradual introduction of 
new vaccines in the national immunization schedule. In 2010 with the 
expenses with pandemic A influenza (H1N1) 2009 vaccine campaign, 
this amount exceeded two billions reais (Fig. 1). 
Despite all these advances, until the mid-90’s, the records of 
vaccination in the country weren’t adequate. At the national level, there 
were only data consolidated by the states (Federative Units) with no 
local (city) information. The ever increasing complexity of the program 
in different areas and in particular on increasing the supply and use of 
vaccines, the knowledge of vaccination coverage in different management 
levels, particularly in the city has become increasingly required and also 
the impact of these on the diseases surveillance.
The first initiatives for a computerized national registry of 
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immunobiological doses applied were from 1994. The Information 
System of Evaluation of National Immunization Program (SIAPI) 
was developed in partnership with the Informatics Department of 
SUS (Datasus). This decentralized system for 100% of the cities and 
computerized in about 5,500 of those, makes available immunization 
data according to immunobiologicals, age group and occurrence of 
immunization, allowing finding out and monitoring vaccination coverage 
in the different target groups of immunization. In addition, other systems 
were created to better provide information about distributed and used 
doses, physical and technical losses, doses used in the CRIES, monitoring 
of AEFI, always with NIP assisting in the decision-making. 
VACCINATION COVERAGE IN BRAZIL
The best way or indicator to evaluate the performance of vaccination 
actions is to analyze the vaccination coverage. The vaccination coverage 
indicator represents the proportion of target population vaccinated, while 
the homogeneity of coverage represents the proportion of cities or area 
within a geographic context that reached the goal set for vaccination 
coverage8.
It is obtained by dividing the number of doses and the target 
population multiplied by one hundred, and the homogeneity of coverage 
is obtained by dividing the number of cities which reached appropriate 
vaccination coverage divided by the total number of cities multiplied 
by one hundred. The calculation of coverage takes into account the last 
dose of the recommended schedule for each vaccine.
Both indicators are tools of agreement between all the levels of SUS 
management (vaccination coverage rates) and they are very important 
for decision making at the different management levels since adequate 
coverage, according to the parameters established for each vaccine, are 
required to obtain control, maintain eliminated and or eradicated vaccine-
preventable diseases under surveillance. 
The rates established for vaccination coverage are: 90% for BCG 
and Rotavirus (VRH); 100% for yellow fever vaccine in areas with 
vaccination’s recommendation; 95% for other vaccines in the pediatric 
schedule and 80% for influenza vaccine. 
At the national and state levels, until the late 80’s, routine vaccination 
coverage did not exceed 70% of the target population. Those low rates 
were insufficient to promote impact on diseases1. Only from the second 
half of the 90’s coverage reached adequate rates and from those years on, 
decrease was seen with emphasis on polio and measles (Fig. 2 and 3). 
Considering the last ten years, the rates of vaccination coverage for 
vaccines in the pediatric schedule were high, reaching or surpassing the 
goals set by PNI. Exceptions are for hepatitis B vaccine, in the first five 
years of the series, they were below the target (95%) and for rotavirus 
vaccine since 2007 (Fig. 4).
Taking as example the vaccination coverage and homogeneity 
of coverage for vaccine DTP+Hib (tetra) in children under one year 
old agreed in the SUS intermanagement agreement in 95% and 70% 
respectively, compliance was checked with the goals of coverage 
throughout the period. With regard to homogeneity, this was reached since 
2006, recording fluctuations in the indicator that ranged from 61.69% 
(2005) to 88.86% (2006) of the 5,565 cities with adequate coverages 
established of ≥ 95% (Fig. 4). A similar pattern was found for other 
vaccines, such as polio and hepatitis B. In relation to MMR vaccine in 
children of one year old, in the same period, the coverages remained 
above target of 95% and homogeneity ranged from 87.23% (2003) to 
69.24% (2010) of the cities with appropriate coverage.
Vaccination campaigns against poliomyelitis in children under five 
years of age were successful in the first five years after the implementation 
in 1980 showing a decrease in both steps within three years of the same 
decade culminating with recrudescence of cases. From 1989 (last case 
reported in Brazil) appropriate rates for vaccination coverage were 
recovered remaining high until the present day (Fig. 2).
In relation to cumulative vaccination coverage of hepatitis B vaccine 
in children and adolescents from 1994 to June 2011, aged 1 to 24 years, 
this was 80% and was inversely proportional to age group, especially in 
groups one to four years, five to 10 years and 11 to 14 years old, when 
the rates already exceed 95% coverage. 
Regarding vaccination with seasonal influenza, the target vaccination 
coverage was originally (1999) set to 70%, remaining until 2007. In 2008 
this was raised to 80% of the target population. Since 1999, the country 
has been showing good compliance of the target population, based on the 
good results of the coverage. These ranged from 67% in 2000, the only 
year with VC < 70%, to 85.73% in 2006, emphasizing that in the last 
five years remained above 75%, and in some years this exceeded 80%. 
The total of doses applied from 1999 on was increasing, consistent with 
the growth of the target population. The number of doses varied from 7.5 
million in 1999 to over 16 million doses in 2011 (Fig. 6).
With respect to immunization campaigns covering young and adult 
population, the national immunization campaign for elimination of 
rubella and congenital rubella syndrome and maintenance of measles 
elimination stood out. In this campaign 67.8 million Brazilians were 
vaccinated, aged 20 to 39 years throughout the country, adding to the 
group 12 - 19 years in the states of Maranhão, Minas Gerais, Mato Grosso, 
Fig.1 -Budget of the National Immunization Program run with the acquisition of biological, 
Brazil, from 1995 to 2011*.
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Rio de Janeiro and Rio Grande do Norte, reaching a vaccination coverage 
of 96.79% of the target population in about 20 weeks of vaccination. 
Considered the largest immunization campaign in the world, due 
to the large number of people to be vaccinated, the immunization 
campaign against rubella was exceeded by the number of doses applied 
by the national immunization campaign to influenza A (H1N1) 2009 
held in 2010. This had as eligible groups health workers; patients with 
chronic illnesses, children between six months and under two years 
old; indigenous; pregnant women and young adults aged 20 to 39 years. 
89.5 million doses of vaccines were reported to be applied within three 
months. Vaccination coverage with a established target of 80% for each 
target group was overcome in most of them, except for pregnant women 
(77.1%) and in adults aged 30 to 39 years (75.3%), highlighting that this 
latter group was only included in the final phase of the campaign, which 
can explain the less favorable results.
Considering the heterogeneity in the vaccination results when the 
situation in the context of cities for any vaccine and target population 
is analyzed, overall results demonstrate the operational capacity of 
PNI in the different SUS management levels. The implementation of 
plans for control and elimination of diseases, the strategies adopted 
for immunization, emphasizing the multivaccination from 1990 on 
the national days for immunization against polio, contributed to 
Fig. 3 - Incidence of poliomyelitis and vaccine coverage in vaccination campaigns with OPV in children under 5 years of age*, Brazil, from 1968 to 2011.
Fig 2 - Incidence rates of measles and vaccination coverage with monovalent measles and triple viral*, Brazil, from 1968 to 2011.
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VC and promoting impact on disease subjected to surveillance in the 
country. 
The implementation of new vaccines is a goal of PNI and important 
advances have occurred in the area of immunization in the country over 
the past two centuries. More vaccines and target groups were gradually 
included in the immunization program in Brazil. When establishing as 
one of the criteria for vaccine deployment the safety and effectiveness 
of the product, PNI has in its favor the credibility in the Program and 
recognition of the population that the vaccine is the primary measure to 
control a significant proportion of diseases. 
The results observed from vaccination coverage in different strategies 
testify in favor to gradual compliance of population to vaccination 
whether routine immunization or in immunization campaigns, and 
have as outcome preventable diseases eradicated, and or under control 
with incalculable benefits to the population. However, the maintenance 
of the current status and progress to obtain new achievements depend 
on obtaining and maintaining high and homogeneous vaccination 
coverage and a surveillance system for adverse events sensitive to detect, 
investigate and intervene in a timely manner. These, among others, are 
fundamental in order to maintain the credibility and success of PNI.
PHARMACOVIGILANCE
Vaccination programs have been one of the safest and most cost-
effective measures in public health. There is no other procedure that 
produces such excellent results in reducing morbidity and mortality 
and also provides so many possibilities, such as the eradication of 
immunepreventable diseases, that led to eradication of smallpox in the 
world, the elimination of poliomyelitis in the Americas since 1994, the 
elimination of measles in Brazil (last case reported in 2000), rubella 
elimination and control of congenital rubella syndrome in Brazil.
The vaccines are given to large groups of healthy individuals, and 
therefore, safety and quality are of great importance. Current vaccines are 
very safe, because they meet strict quality parameters from production to 
their application. In general, they are among the safest pharmaceutical 
products for human use, providing broad benefits to public health of a 
country.
Unfortunately, like all medical interventions, the immunization 
procedures are not completely safe. With the increase in vaccination 
coverage, both in developed and developing countries, the reduction of 
immunepreventable diseases occurs; however, there is a growing concern 
about the safety of vaccines, i.e., with the increased number of adverse 
events following immunization (AEFI).
Immunization programs have the responsibility to address the 
public concern related to vaccines by providing workers with updated 
information on safe immunization practices. 
Safe vaccination is a priority component of immunization programs 
that seeks to ensure the use of quality vaccines, and this quality control 
in Brazil is carried out by the National Institute for Quality Control in 
Health, Oswaldo Cruz Foundation (Instituto Nacional de Controle de 
Qualidade em Saúde da Fundação Oswaldo Cruz (INCQS/FIOCRUZ)); 
the shipping and storage with appropriate packaging, the use of safe 
Fig. 5 - Vaccination accumulated hepatitis B vaccine by age group, Brazil, from 1994 to 2011.
Fig. 4 - Vaccination coverage (%) by type of vaccination in the child’s, Brazil, 2001 to 2011.
Fig. 6 - Doses administered and vaccine coverage of influenza vaccine in elderly people, 
Brazil 1999 to 2011*.
greater compliance of the population. Added to these, the expansion 
of health services and the decentralization process, factors that directly 
or indirectly contribute to the improvement of the access, increasing 
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injection practices from appropriate administration to final disposal, the 
performance of surveillance of adverse events following immunization 
with early and efficient investigations and strengthening alliances with the 
media according to the perception of the population using clear messages 
to the public about the strategies, priorities and safety of vaccination.
An adverse event following immunization (AEFI) is any health 
problem temporally related to vaccination, caused or not by the 
vaccine administered. Such events may be related to the composition 
of the vaccine, the individuals vaccinated, the technique used for 
administration (programming errors), or overlapping with other health 
problems. Given the nature and characteristics of immunebiologicals, 
as well as the knowledge already available from experience, events 
can be expected: fever, local pain, myalgia, headache, hyporesponsive 
hypotonic episode, among others, or unexpected, which are those not 
previously identified (e.g.: new vaccines) or resulted from problems 
related to production (inappropriate endotoxin content in certain 
vaccines causing febrile reactions similar to sepsis, contamination of 
batches causing abscesses)9.
For best results all the people who participate in safe immunization 
activities should exercise their activities in an integrated manner: 
National Regulatory Agency - Anvisa, epidemiological surveillance, 
national laboratory for quality control, anatomical pathology laboratories, 
professional organizations, communicators, vaccine producers, World 
Health Organization/Pan American Health Organization and cooperating 
bodies10.
Since 1991 the World Health Organization (WHO) recommends 
surveillance of adverse events following immunization. Since 2000, the 
Brazilian Ministry of Health implemented the information system for 
surveillance of adverse events following immunization (SI-EAPV) and 
because of the importance, by the ordinance of the Secretariat of Health 
Surveillance, this was introduced as an injury of compulsory reporting (Pt 
SVS/MS nº 33 of 25/Jul/2005), and according to Resolution RDC Anvisa 
nº 4 of 10/Feb/2009, which sets forth the standards of pharmacovigilance 
to record holders of medicinal products for human use, who must notify, 
as soon as possible, any adverse event ocurring in the national territory, 
setting the maximum period of seven days from the date of knowledge 
of the adverse event information.
The objectives of AEFI surveillance are: to regulate the recognition 
and procedure in the case of adverse events following immunization 
(AEFI), to identify serious adverse events, new and/or rare, to establish or 
rule out a causal relationship with the vaccine, to identify more reactional 
batches, to detect, correct and prevent programmatic or operational errors, 
to update contraindications and analysis of risks and benefits, to estimate 
incidence rates and generate new hypotheses.
All public and private health services offering vaccine rooms, 
basic health units, emergency care and hospitals are responsible for 
notifying AEFI. Notification is a mechanism that helps maintain an 
active monitoring system and a status of permanent alertness of the 
health worker for the detection of AEFI10. Also highlighted is that in 
any epidemiological situation, serious AEFI should be reported within 
24 hours from the occurrence, from local to national level following 
the flowchart determined by the National Immunization Program of the 
Ministry of Health.
Every event in which the patient, parents or guardians, the public, 
health professionals consider related to the administration of a vaccine 
should be investigated in the place of occurrence. If the period of onset 
and the symptoms/signs indicate the possibility that this event has a 
relationship with the vaccine, further investigation should be immediately 
initiated with assistance of state and national levels. The purpose of the 
investigation is to confirm or discard the event notified, to determine 
whether there are other possible causes, to check if this is an isolated 
event and to report to the parties involved.
The early, honest and efficient communication of the results of one 
investigation assure the integrity of immunization programs11. 
International experience shows that the supply and use of safe 
and quality vaccines is a prerequisite for the high compliance of the 
population, as well as health workers, to the immunization programs. 
However, it is expected that a healthy and democratic debate about risks 
and benefits of immunization is ruled by the need for caution and great 
responsibility on issues of such relevance to the health of Brazilian 
population12.
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